2017-03-23,Biotech Premarket Movers: Insys, Ultragenyx, Alexion
2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
2017-03-02,Ultragenyx To Present At Upcoming Investor Conferences
2017-02-16,Ultragenyx Reports Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-02-10,Ultragenyx To Present At Leerink Partners Global Healthcare Conference
2017-02-09,Ultragenyx To Host Conference Call For Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-01-05,Ultragenyx And Kyowa Kirin International Announce Marketing Authorization Application For KRN23 Filed And Accepted For Review By European Medicines Agency
2017-01-04,Ultragenyx To Present At J.P. Morgan Healthcare Conference
2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2016-11-17,Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
2016-11-11,Ultragenyx Announces Withdrawal Of Marketing Authorization Application For Aceneuramic Acid Prolonged Release (Ace-ER) In The European Union
2016-11-08,Ultragenyx To Present At Upcoming Investor Conferences
2016-11-07,Ultragenyx Reports Third Quarter 2016 Financial Results And Corporate Update
2016-10-31,Ultragenyx To Host Conference Call For Third Quarter 2016 Financial Results And Corporate Update
2016-10-26,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Pediatric Patients With X-Linked Hypophosphatemia (XLH)
2016-09-27,Ultragenyx To Present At Leerink Partners Roundtable Series
2016-09-19,Ultragenyx Reports Positive Interim Data From Pediatric And Adult Phase 2 Studies Of KRN23 In X-Linked Hypophosphatemia
2016-09-18,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-09-16,Ultragenyx To Host Conference Call To Discuss KRN23 Data Presented At ASBMR 2016 Annual Meeting
2016-09-01,Ultragenyx To Present At Baird 2016 Global Healthcare Conference
2016-08-23,Ultragenyx Announces KRN23 Data Presentations At ASBMR 2016 Annual Meeting
2016-08-09,Ultragenyx To Present At Upcoming Investor Conferences
2016-08-08,Ultragenyx Reports Second Quarter 2016 Financial Results And Corporate Update
2016-08-01,Ultragenyx To Host Conference Call For Second Quarter 2016 Financial Results And Corporate Update
2016-07-28,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2016-07-27,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Aceneuramic Acid Extended Release (Ace-ER) In GNE Myopathy
2016-07-26,These 5 Stocks Are Breaking Out This Summer
2016-07-14,Ultragenyx Announces Positive Topline Data From Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2016-07-13,Ultragenyx To Present Phase 3 Data For Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 (MPS 7) At 14th International Symposium On MPS And Related Diseases
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-28,Ultragenyx Receives Breakthrough Therapy Designation For KRN23 In Pediatric Patients With X-Linked Hypophosphatemia
2016-06-20,Ultragenyx Appoints Karah Parschauer As Executive Vice President, General Counsel
2016-06-07,Ultragenyx And Takeda Enter Into A Collaboration To Develop And Commercialize Therapies For Rare Genetic Diseases
2016-06-01,Ultragenyx To Present At Upcoming Investor Conferences
2016-05-09,Ultragenyx Reports First Quarter 2016 Financial Results And Corporate Update
2016-05-06,Ultragenyx To Present At Bank Of America Merrill Lynch Healthcare Conference
2016-04-29,Ultragenyx To Host Conference Call For First Quarter 2016 Financial Results And Corporate Update
2016-04-21,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-03-23,Ultragenyx And Saint Louis University's Center For World Health And Medicine Announce Research Collaboration To Advance Muscular Dystrophy Treatment
2016-03-21,Ultragenyx Appoints Lars Ekman, M.D., Ph.D., To Board Of Directors
2016-03-02,Ultragenyx To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-01,Ultragenyx Announces Data Presentations Of RhGUS And RhPPCA At 12th Annual WORLD Symposium™
2016-02-25,Ultragenyx Reports Fourth Quarter 2015 And Full-Year 2015 Financial Results And Corporate Update
2016-02-19,Ultragenyx Pharmaceutical (RARE) Stock Gets 'Outperform' Rating at Leerink
2016-02-18,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2015 Financial Results And Corporate Update
2016-02-09,Ultragenyx To Present At The Leerink Partners Annual Healthcare Conference
2016-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2015-12-03,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2015-12-02,Ultragenyx To Present At The Oppenheimer Annual Healthcare Conference
2015-12-02,Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-11-11,Ultragenyx To Present At Upcoming Investor Conferences
2015-11-09,Ultragenyx Reports Third Quarter 2015 Financial Results And Corporate Update
2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
2015-11-03,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2015-11-03,Ultragenyx To Host Conference Call For Third Quarter 2015 Financial Results And Corporate Update
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-13,Short Interest In Ultragenyx Pharmaceutical Falls 16.8%
2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2015-10-02,Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed And Accepted For Review By European Medicines Agency
2015-09-04,Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?
2015-09-02,Ultragenyx To Present At The Baird Health Care Conference
2015-09-01,Ultragenyx Announces Presentation Of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin
2015-08-13,Ultragenyx Reports Second Quarter 2015 Financial Results And Corporate Update
2015-08-13,Ultragenyx Pharmaceutical Stock Sees Short Interest Decline 25.7%
2015-08-06,Ultragenyx To Host Conference Call For Second Quarter 2015 Financial Results And Corporate Update
2015-08-05,Ultragenyx Announces Initiation Of Phase 2 Study Of Recombinant Human Beta-Glucuronidase In Patients Under Five Years Old With Mucopolysaccharidosis 7
2015-08-04,Ultragenyx To Present At Upcoming Investor Conferences
2015-07-29,Short Interest Jumps 28.6% For RARE
2015-07-27,Analysts' Actions -- Cigna, Monster Beverage, Qualcomm and More
2015-07-21,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-20,Ultragenyx Appoints John Pinion As Chief Quality Operations Officer And Senior Vice President, Analytical Sciences And Research
2015-07-15,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-07-14,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-07-09,Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-06-25,Ultragenyx Names Daniel G. Welch As Chairman Of The Board
2015-06-22,Ultragenyx Appoints Jayson Dallas, M.D., As Chief Commercial Officer And Senior Vice President
2015-06-17,Ultragenyx Pharmaceutical Larger Than S&P 500 Component QEP Resources
2015-06-17,Ultragenyx To Present At The JMP Securities Healthcare Conference
2015-06-08,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2015-06-04,Ultragenyx Appoints Dennis Huang As Chief Technical Operations Officer And Senior Vice President
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-02,Ultragenyx Releases Positive 16-Week Interim Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-05-28,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of Aceneuramic Acid (Sialic Acid) Extended Release In GNE Myopathy
2015-05-26,Ultragenyx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-11,Ultragenyx Reports First Quarter 2015 Financial Results And Corporate Update
2015-05-05,Ultragenyx To Host Conference Call For First Quarter 2015 Financial Results And Corporate Update
2015-04-23,Ultragenyx Granted Additional Orphan Drug Designations For Triheptanoin
2015-04-22,Ultragenyx Announces Positive Data From Investigator-Sponsored Trial Of Triheptanoin In Glucose Transporter Type-1 Deficiency Syndrome
2015-04-13,Ultragenyx Appoints Daniel G. Welch To Board Of Directors
2015-03-25,Ultragenyx Reports Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-20,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-09,Ultragenyx Announces Presentation Of Disease Burden Data In Adult Patients With X-Linked Hypophosphatemia
2015-03-05,Use Options For A Chance To Buy RARE At A 31% Discount
2015-03-04,Ultragenyx To Present At The Barclays Global Healthcare Conference
2015-02-25,Ultragenyx To Present At The Cowen And Company 35th Annual Health Care Conference In Boston
2015-02-24,Ultragenyx Appoints Michael Narachi To Board Of Directors
2015-02-17,Ultragenyx Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-02-10,Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2015-02-04,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-02-03,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-01-12,Ultragenyx Announces Intent To File For Conditional Approval In Europe For Sialic Acid Extended-Release Tablets In Hereditary Inclusion Body Myopathy
2015-01-07,Ultragenyx Announces License Of Intellectual Property Related To The Treatment Of Huntington's Disease With Triheptanoin
2015-01-06,Ultragenyx Initiates New Development Program Studying KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2015-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2014-12-15,Ultragenyx Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2014-12-03,Ultragenyx To Present At The Oppenheimer Healthcare Conference
2014-11-10,Ultragenyx Reports Third Quarter 2014 Financial Results And Corporate Update
2014-11-04,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2014-10-30,Ultragenyx Granted EU Orphan Drug Designation For KRN23 For The Treatment Of X-Linked Hypophosphatemia
2014-10-27,Ultragenyx Granted Orphan Drug Designation For Triheptanoin For The Treatment Of Glucose Transporter Type-1 Deficiency Syndrome
2014-10-20,Use Options For a Chance To Buy RARE at a 31% Discount
2014-10-13,Ultragenyx Announces Interim Data From Phase 2 Extension Study Of Sialic Acid Extended-Release At International Congress Of The World Muscle Society
2014-09-24,Ultragenyx To Present At The Leerink Partners Rare Disease Roundtable
2014-09-15,Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia
2014-09-04,Ultragenyx To Present At The Morgan Stanley Global Healthcare Conference
2014-09-03,Ultragenyx Announces Positive Interim Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2014-08-27,Ultragenyx To Present At The Baird Health Care Conference
2014-08-26,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-12,Ultragenyx Pharmaceutical Stock Sees Short Interest Expand By 33.2%
2014-08-11,Ultragenyx Reports Second Quarter 2014 Financial Results And Corporate Update
2014-08-07,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-06,Ultragenyx To Present At Upcoming Investor Conferences
2014-08-05,Ultragenyx Announces License Of Intellectual Property For The Treatment Of Epilepsy And Other Seizure-Related Disorders With Triheptanoin
2014-07-31,3 Biotech Stocks Breaking Out on Big Volume
2014-07-25,Short Interest In Ultragenyx Pharmaceutical Decreases By 17%
2014-07-23,Ultragenyx Appoints Sunil Agarwal, M.D. As Chief Medical Officer And Senior Vice President
2014-07-21,3 Biotech Stocks Breaking Out on Big Volume
2014-07-14,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2014-07-09,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2014-07-07,Ultragenyx Announces Proposed Public Offering Of Common Stock
2014-06-27,'Fast Money' Recap: Rangebound Treasury Yields
2014-06-21,'Mad Money' Lightning Round: Globalstar Is a Real Winner
2014-06-20,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2014-04-09,'Fast Money' Recap: S&P Snapback
2014-02-06,Top Insider Trades: DRNA RGLS RARE CARA
2007-09-18,Darden Earnings Jump
2007-08-21,Stockpickr Lists: Buffett Eyeing Countrywide?
2007-08-17,Friday's Winners & Losers: Rare Hospitality
2007-08-16,Darden Buying Rare
2007-07-13,Stock Upgrades, Downgrades from TheStreet.com Ratings
2007-04-27,Restaurants Reeking
2007-03-14,Rare Hospitality's Prospects Juicy
2007-02-16,Friday's Analysts' Upgrades and Downgrades
2007-01-18,Thursday's Analysts' Upgrades and Downgrades
2005-10-20,Stocks in Motion: MoneyGram
2004-02-05,A Rare Find Among Restaurants
2004-01-22,A New Year, a New Barrel
2004-01-16,Restaurant Stocks Survive Mad Cow
2004-01-12,Nasdaq Hits a New 30-Month High
2003-10-08,Restaurant Earnings a Smorgasbord
2003-09-03,Bottom of the Barrel: Old-Timers Take the Field
2003-08-21,Bottom of the Barrel: The Art of the Sale
2003-04-07,Wendy's Same-Store Sales Dip
2003-04-04,Rare Hospitality Sees Earnings Rising
2003-03-19,Bottom of the Barrel: Small-Caps for Uncertain Times
2003-01-09,Bottom of the Barrel: Cleaning Out the Portfolio
2002-07-31,Bottom of the Barrel: Tropical Treat With Hawaiian Electric
2002-07-24,Bottom of the Barrel: What to Do When Everything Sinks
2002-04-10,Bottom of the Barrel: Heads and Tails of the First Quarter
2002-03-13,Bottom of the Barrel: The Portfolio Gets a Spring Cleaning
2002-02-20,Bottom of the Barrel: A Rare Chance in the Restaurant Business
2017-03-23,Biotech Premarket Movers: Insys, Ultragenyx, Alexion
2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
2017-03-02,Ultragenyx To Present At Upcoming Investor Conferences
2017-02-16,Ultragenyx Reports Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-02-10,Ultragenyx To Present At Leerink Partners Global Healthcare Conference
2017-02-09,Ultragenyx To Host Conference Call For Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-01-05,Ultragenyx And Kyowa Kirin International Announce Marketing Authorization Application For KRN23 Filed And Accepted For Review By European Medicines Agency
2017-01-04,Ultragenyx To Present At J.P. Morgan Healthcare Conference
2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2016-11-17,Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
2016-11-11,Ultragenyx Announces Withdrawal Of Marketing Authorization Application For Aceneuramic Acid Prolonged Release (Ace-ER) In The European Union
2016-11-08,Ultragenyx To Present At Upcoming Investor Conferences
2016-11-07,Ultragenyx Reports Third Quarter 2016 Financial Results And Corporate Update
2016-10-31,Ultragenyx To Host Conference Call For Third Quarter 2016 Financial Results And Corporate Update
2016-10-26,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Pediatric Patients With X-Linked Hypophosphatemia (XLH)
2016-09-27,Ultragenyx To Present At Leerink Partners Roundtable Series
2016-09-19,Ultragenyx Reports Positive Interim Data From Pediatric And Adult Phase 2 Studies Of KRN23 In X-Linked Hypophosphatemia
2016-09-18,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-09-16,Ultragenyx To Host Conference Call To Discuss KRN23 Data Presented At ASBMR 2016 Annual Meeting
2016-09-01,Ultragenyx To Present At Baird 2016 Global Healthcare Conference
2016-08-23,Ultragenyx Announces KRN23 Data Presentations At ASBMR 2016 Annual Meeting
2016-08-09,Ultragenyx To Present At Upcoming Investor Conferences
2016-08-08,Ultragenyx Reports Second Quarter 2016 Financial Results And Corporate Update
2016-08-01,Ultragenyx To Host Conference Call For Second Quarter 2016 Financial Results And Corporate Update
2016-07-28,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2016-07-27,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Aceneuramic Acid Extended Release (Ace-ER) In GNE Myopathy
2016-07-26,These 5 Stocks Are Breaking Out This Summer
2016-07-14,Ultragenyx Announces Positive Topline Data From Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2016-07-13,Ultragenyx To Present Phase 3 Data For Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 (MPS 7) At 14th International Symposium On MPS And Related Diseases
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-28,Ultragenyx Receives Breakthrough Therapy Designation For KRN23 In Pediatric Patients With X-Linked Hypophosphatemia
2016-06-20,Ultragenyx Appoints Karah Parschauer As Executive Vice President, General Counsel
2016-06-07,Ultragenyx And Takeda Enter Into A Collaboration To Develop And Commercialize Therapies For Rare Genetic Diseases
2016-06-01,Ultragenyx To Present At Upcoming Investor Conferences
2016-05-09,Ultragenyx Reports First Quarter 2016 Financial Results And Corporate Update
2016-05-06,Ultragenyx To Present At Bank Of America Merrill Lynch Healthcare Conference
2016-04-29,Ultragenyx To Host Conference Call For First Quarter 2016 Financial Results And Corporate Update
2016-04-21,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-03-23,Ultragenyx And Saint Louis University's Center For World Health And Medicine Announce Research Collaboration To Advance Muscular Dystrophy Treatment
2016-03-21,Ultragenyx Appoints Lars Ekman, M.D., Ph.D., To Board Of Directors
2016-03-02,Ultragenyx To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-01,Ultragenyx Announces Data Presentations Of RhGUS And RhPPCA At 12th Annual WORLD Symposium™
2016-02-25,Ultragenyx Reports Fourth Quarter 2015 And Full-Year 2015 Financial Results And Corporate Update
2016-02-19,Ultragenyx Pharmaceutical (RARE) Stock Gets 'Outperform' Rating at Leerink
2016-02-18,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2015 Financial Results And Corporate Update
2016-02-09,Ultragenyx To Present At The Leerink Partners Annual Healthcare Conference
2016-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2015-12-03,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2015-12-02,Ultragenyx To Present At The Oppenheimer Annual Healthcare Conference
2015-12-02,Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-11-11,Ultragenyx To Present At Upcoming Investor Conferences
2015-11-09,Ultragenyx Reports Third Quarter 2015 Financial Results And Corporate Update
2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
2015-11-03,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2015-11-03,Ultragenyx To Host Conference Call For Third Quarter 2015 Financial Results And Corporate Update
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-13,Short Interest In Ultragenyx Pharmaceutical Falls 16.8%
2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2015-10-02,Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed And Accepted For Review By European Medicines Agency
2015-09-04,Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?
2015-09-02,Ultragenyx To Present At The Baird Health Care Conference
2015-09-01,Ultragenyx Announces Presentation Of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin
2015-08-13,Ultragenyx Reports Second Quarter 2015 Financial Results And Corporate Update
2015-08-13,Ultragenyx Pharmaceutical Stock Sees Short Interest Decline 25.7%
2015-08-06,Ultragenyx To Host Conference Call For Second Quarter 2015 Financial Results And Corporate Update
2015-08-05,Ultragenyx Announces Initiation Of Phase 2 Study Of Recombinant Human Beta-Glucuronidase In Patients Under Five Years Old With Mucopolysaccharidosis 7
2015-08-04,Ultragenyx To Present At Upcoming Investor Conferences
2015-07-29,Short Interest Jumps 28.6% For RARE
2015-07-27,Analysts' Actions -- Cigna, Monster Beverage, Qualcomm and More
2015-07-21,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-20,Ultragenyx Appoints John Pinion As Chief Quality Operations Officer And Senior Vice President, Analytical Sciences And Research
2015-07-15,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-07-14,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-07-09,Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-06-25,Ultragenyx Names Daniel G. Welch As Chairman Of The Board
2015-06-22,Ultragenyx Appoints Jayson Dallas, M.D., As Chief Commercial Officer And Senior Vice President
2015-06-17,Ultragenyx Pharmaceutical Larger Than S&P 500 Component QEP Resources
2015-06-17,Ultragenyx To Present At The JMP Securities Healthcare Conference
2015-06-08,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2015-06-04,Ultragenyx Appoints Dennis Huang As Chief Technical Operations Officer And Senior Vice President
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-02,Ultragenyx Releases Positive 16-Week Interim Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-05-28,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of Aceneuramic Acid (Sialic Acid) Extended Release In GNE Myopathy
2015-05-26,Ultragenyx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-11,Ultragenyx Reports First Quarter 2015 Financial Results And Corporate Update
2015-05-05,Ultragenyx To Host Conference Call For First Quarter 2015 Financial Results And Corporate Update
2015-04-23,Ultragenyx Granted Additional Orphan Drug Designations For Triheptanoin
2015-04-22,Ultragenyx Announces Positive Data From Investigator-Sponsored Trial Of Triheptanoin In Glucose Transporter Type-1 Deficiency Syndrome
2015-04-13,Ultragenyx Appoints Daniel G. Welch To Board Of Directors
2015-03-25,Ultragenyx Reports Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-20,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-09,Ultragenyx Announces Presentation Of Disease Burden Data In Adult Patients With X-Linked Hypophosphatemia
2015-03-05,Use Options For A Chance To Buy RARE At A 31% Discount
2015-03-04,Ultragenyx To Present At The Barclays Global Healthcare Conference
2015-02-25,Ultragenyx To Present At The Cowen And Company 35th Annual Health Care Conference In Boston
2015-02-24,Ultragenyx Appoints Michael Narachi To Board Of Directors
2015-02-17,Ultragenyx Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-02-10,Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2015-02-04,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-02-03,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-01-12,Ultragenyx Announces Intent To File For Conditional Approval In Europe For Sialic Acid Extended-Release Tablets In Hereditary Inclusion Body Myopathy
2015-01-07,Ultragenyx Announces License Of Intellectual Property Related To The Treatment Of Huntington's Disease With Triheptanoin
2015-01-06,Ultragenyx Initiates New Development Program Studying KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2015-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2014-12-15,Ultragenyx Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2014-12-03,Ultragenyx To Present At The Oppenheimer Healthcare Conference
2014-11-10,Ultragenyx Reports Third Quarter 2014 Financial Results And Corporate Update
2014-11-04,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2014-10-30,Ultragenyx Granted EU Orphan Drug Designation For KRN23 For The Treatment Of X-Linked Hypophosphatemia
2014-10-27,Ultragenyx Granted Orphan Drug Designation For Triheptanoin For The Treatment Of Glucose Transporter Type-1 Deficiency Syndrome
2014-10-20,Use Options For a Chance To Buy RARE at a 31% Discount
2014-10-13,Ultragenyx Announces Interim Data From Phase 2 Extension Study Of Sialic Acid Extended-Release At International Congress Of The World Muscle Society
2014-09-24,Ultragenyx To Present At The Leerink Partners Rare Disease Roundtable
2014-09-15,Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia
2014-09-04,Ultragenyx To Present At The Morgan Stanley Global Healthcare Conference
2014-09-03,Ultragenyx Announces Positive Interim Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2014-08-27,Ultragenyx To Present At The Baird Health Care Conference
2014-08-26,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-12,Ultragenyx Pharmaceutical Stock Sees Short Interest Expand By 33.2%
2014-08-11,Ultragenyx Reports Second Quarter 2014 Financial Results And Corporate Update
2014-08-07,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-06,Ultragenyx To Present At Upcoming Investor Conferences
2014-08-05,Ultragenyx Announces License Of Intellectual Property For The Treatment Of Epilepsy And Other Seizure-Related Disorders With Triheptanoin
2014-07-31,3 Biotech Stocks Breaking Out on Big Volume
2014-07-25,Short Interest In Ultragenyx Pharmaceutical Decreases By 17%
2014-07-23,Ultragenyx Appoints Sunil Agarwal, M.D. As Chief Medical Officer And Senior Vice President
2014-07-21,3 Biotech Stocks Breaking Out on Big Volume
2014-07-14,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2014-07-09,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2014-07-07,Ultragenyx Announces Proposed Public Offering Of Common Stock
2014-06-27,'Fast Money' Recap: Rangebound Treasury Yields
2014-06-21,'Mad Money' Lightning Round: Globalstar Is a Real Winner
2014-06-20,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2014-04-09,'Fast Money' Recap: S&P Snapback
2014-02-06,Top Insider Trades: DRNA RGLS RARE CARA
2007-09-18,Darden Earnings Jump
2007-08-21,Stockpickr Lists: Buffett Eyeing Countrywide?
2007-08-17,Friday's Winners & Losers: Rare Hospitality
2007-08-16,Darden Buying Rare
2007-07-13,Stock Upgrades, Downgrades from TheStreet.com Ratings
2007-04-27,Restaurants Reeking
2007-03-14,Rare Hospitality's Prospects Juicy
2007-02-16,Friday's Analysts' Upgrades and Downgrades
2007-01-18,Thursday's Analysts' Upgrades and Downgrades
2005-10-20,Stocks in Motion: MoneyGram
2004-02-05,A Rare Find Among Restaurants
2004-01-22,A New Year, a New Barrel
2004-01-16,Restaurant Stocks Survive Mad Cow
2004-01-12,Nasdaq Hits a New 30-Month High
2003-10-08,Restaurant Earnings a Smorgasbord
2003-09-03,Bottom of the Barrel: Old-Timers Take the Field
2003-08-21,Bottom of the Barrel: The Art of the Sale
2003-04-07,Wendy's Same-Store Sales Dip
2003-04-04,Rare Hospitality Sees Earnings Rising
2003-03-19,Bottom of the Barrel: Small-Caps for Uncertain Times
2003-01-09,Bottom of the Barrel: Cleaning Out the Portfolio
2002-07-31,Bottom of the Barrel: Tropical Treat With Hawaiian Electric
2002-07-24,Bottom of the Barrel: What to Do When Everything Sinks
2002-04-10,Bottom of the Barrel: Heads and Tails of the First Quarter
2002-03-13,Bottom of the Barrel: The Portfolio Gets a Spring Cleaning
2002-02-20,Bottom of the Barrel: A Rare Chance in the Restaurant Business
2017-03-23,Biotech Premarket Movers: Insys, Ultragenyx, Alexion
2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
2017-03-02,Ultragenyx To Present At Upcoming Investor Conferences
2017-02-16,Ultragenyx Reports Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-02-10,Ultragenyx To Present At Leerink Partners Global Healthcare Conference
2017-02-09,Ultragenyx To Host Conference Call For Fourth Quarter And Full Year 2016 Financial Results And Corporate Update
2017-01-05,Ultragenyx And Kyowa Kirin International Announce Marketing Authorization Application For KRN23 Filed And Accepted For Review By European Medicines Agency
2017-01-04,Ultragenyx To Present At J.P. Morgan Healthcare Conference
2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2016-11-17,Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
2016-11-11,Ultragenyx Announces Withdrawal Of Marketing Authorization Application For Aceneuramic Acid Prolonged Release (Ace-ER) In The European Union
2016-11-08,Ultragenyx To Present At Upcoming Investor Conferences
2016-11-07,Ultragenyx Reports Third Quarter 2016 Financial Results And Corporate Update
2016-10-31,Ultragenyx To Host Conference Call For Third Quarter 2016 Financial Results And Corporate Update
2016-10-26,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Pediatric Patients With X-Linked Hypophosphatemia (XLH)
2016-09-27,Ultragenyx To Present At Leerink Partners Roundtable Series
2016-09-19,Ultragenyx Reports Positive Interim Data From Pediatric And Adult Phase 2 Studies Of KRN23 In X-Linked Hypophosphatemia
2016-09-18,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-09-16,Ultragenyx To Host Conference Call To Discuss KRN23 Data Presented At ASBMR 2016 Annual Meeting
2016-09-01,Ultragenyx To Present At Baird 2016 Global Healthcare Conference
2016-08-23,Ultragenyx Announces KRN23 Data Presentations At ASBMR 2016 Annual Meeting
2016-08-09,Ultragenyx To Present At Upcoming Investor Conferences
2016-08-08,Ultragenyx Reports Second Quarter 2016 Financial Results And Corporate Update
2016-08-01,Ultragenyx To Host Conference Call For Second Quarter 2016 Financial Results And Corporate Update
2016-07-28,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2016-07-27,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Aceneuramic Acid Extended Release (Ace-ER) In GNE Myopathy
2016-07-26,These 5 Stocks Are Breaking Out This Summer
2016-07-14,Ultragenyx Announces Positive Topline Data From Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2016-07-13,Ultragenyx To Present Phase 3 Data For Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 (MPS 7) At 14th International Symposium On MPS And Related Diseases
2016-06-29,16 Biopharma Companies Besides Medivation That Are Attractive Targets
2016-06-28,Ultragenyx Receives Breakthrough Therapy Designation For KRN23 In Pediatric Patients With X-Linked Hypophosphatemia
2016-06-20,Ultragenyx Appoints Karah Parschauer As Executive Vice President, General Counsel
2016-06-07,Ultragenyx And Takeda Enter Into A Collaboration To Develop And Commercialize Therapies For Rare Genetic Diseases
2016-06-01,Ultragenyx To Present At Upcoming Investor Conferences
2016-05-09,Ultragenyx Reports First Quarter 2016 Financial Results And Corporate Update
2016-05-06,Ultragenyx To Present At Bank Of America Merrill Lynch Healthcare Conference
2016-04-29,Ultragenyx To Host Conference Call For First Quarter 2016 Financial Results And Corporate Update
2016-04-21,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2016-03-23,Ultragenyx And Saint Louis University's Center For World Health And Medicine Announce Research Collaboration To Advance Muscular Dystrophy Treatment
2016-03-21,Ultragenyx Appoints Lars Ekman, M.D., Ph.D., To Board Of Directors
2016-03-02,Ultragenyx To Present At The Cowen And Company 36th Annual Health Care Conference
2016-03-01,Ultragenyx Announces Data Presentations Of RhGUS And RhPPCA At 12th Annual WORLD Symposium™
2016-02-25,Ultragenyx Reports Fourth Quarter 2015 And Full-Year 2015 Financial Results And Corporate Update
2016-02-19,Ultragenyx Pharmaceutical (RARE) Stock Gets 'Outperform' Rating at Leerink
2016-02-18,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2015 Financial Results And Corporate Update
2016-02-09,Ultragenyx To Present At The Leerink Partners Annual Healthcare Conference
2016-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2015-12-03,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
2015-12-02,Ultragenyx To Present At The Oppenheimer Annual Healthcare Conference
2015-12-02,Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-11-11,Ultragenyx To Present At Upcoming Investor Conferences
2015-11-09,Ultragenyx Reports Third Quarter 2015 Financial Results And Corporate Update
2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
2015-11-03,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2015-11-03,Ultragenyx To Host Conference Call For Third Quarter 2015 Financial Results And Corporate Update
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-29,Ultragenyx Pharmaceutical And Arcturus Therapeutics Announce A Research Collaboration And License Agreement To Develop RNA Therapeutics For Rare Diseases
2015-10-13,Short Interest In Ultragenyx Pharmaceutical Falls 16.8%
2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
2015-10-02,Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed And Accepted For Review By European Medicines Agency
2015-09-04,Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?
2015-09-02,Ultragenyx To Present At The Baird Health Care Conference
2015-09-01,Ultragenyx Announces Presentation Of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin
2015-08-13,Ultragenyx Reports Second Quarter 2015 Financial Results And Corporate Update
2015-08-13,Ultragenyx Pharmaceutical Stock Sees Short Interest Decline 25.7%
2015-08-06,Ultragenyx To Host Conference Call For Second Quarter 2015 Financial Results And Corporate Update
2015-08-05,Ultragenyx Announces Initiation Of Phase 2 Study Of Recombinant Human Beta-Glucuronidase In Patients Under Five Years Old With Mucopolysaccharidosis 7
2015-08-04,Ultragenyx To Present At Upcoming Investor Conferences
2015-07-29,Short Interest Jumps 28.6% For RARE
2015-07-27,Analysts' Actions -- Cigna, Monster Beverage, Qualcomm and More
2015-07-21,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-20,Ultragenyx Appoints John Pinion As Chief Quality Operations Officer And Senior Vice President, Analytical Sciences And Research
2015-07-15,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-07-14,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-07-09,Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-06-25,Ultragenyx Names Daniel G. Welch As Chairman Of The Board
2015-06-22,Ultragenyx Appoints Jayson Dallas, M.D., As Chief Commercial Officer And Senior Vice President
2015-06-17,Ultragenyx Pharmaceutical Larger Than S&P 500 Component QEP Resources
2015-06-17,Ultragenyx To Present At The JMP Securities Healthcare Conference
2015-06-08,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2015-06-04,Ultragenyx Appoints Dennis Huang As Chief Technical Operations Officer And Senior Vice President
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-02,Ultragenyx Releases Positive 16-Week Interim Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
2015-05-28,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of Aceneuramic Acid (Sialic Acid) Extended Release In GNE Myopathy
2015-05-26,Ultragenyx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-11,Ultragenyx Reports First Quarter 2015 Financial Results And Corporate Update
2015-05-05,Ultragenyx To Host Conference Call For First Quarter 2015 Financial Results And Corporate Update
2015-04-23,Ultragenyx Granted Additional Orphan Drug Designations For Triheptanoin
2015-04-22,Ultragenyx Announces Positive Data From Investigator-Sponsored Trial Of Triheptanoin In Glucose Transporter Type-1 Deficiency Syndrome
2015-04-13,Ultragenyx Appoints Daniel G. Welch To Board Of Directors
2015-03-25,Ultragenyx Reports Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-20,Ultragenyx To Host Conference Call For Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update
2015-03-09,Ultragenyx Announces Presentation Of Disease Burden Data In Adult Patients With X-Linked Hypophosphatemia
2015-03-05,Use Options For A Chance To Buy RARE At A 31% Discount
2015-03-04,Ultragenyx To Present At The Barclays Global Healthcare Conference
2015-02-25,Ultragenyx To Present At The Cowen And Company 35th Annual Health Care Conference In Boston
2015-02-24,Ultragenyx Appoints Michael Narachi To Board Of Directors
2015-02-17,Ultragenyx Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-02-10,Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2015-02-04,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2015-02-03,Ultragenyx Announces Proposed Public Offering Of Common Stock
2015-01-12,Ultragenyx Announces Intent To File For Conditional Approval In Europe For Sialic Acid Extended-Release Tablets In Hereditary Inclusion Body Myopathy
2015-01-07,Ultragenyx Announces License Of Intellectual Property Related To The Treatment Of Huntington's Disease With Triheptanoin
2015-01-06,Ultragenyx Initiates New Development Program Studying KRN23 For The Treatment Of Tumor-Induced Osteomalacia
2015-01-05,Ultragenyx To Present At The J.P. Morgan Healthcare Conference
2014-12-15,Ultragenyx Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7
2014-12-03,Ultragenyx To Present At The Oppenheimer Healthcare Conference
2014-11-10,Ultragenyx Reports Third Quarter 2014 Financial Results And Corporate Update
2014-11-04,Ultragenyx To Present At The Credit Suisse Annual Healthcare Conference
2014-10-30,Ultragenyx Granted EU Orphan Drug Designation For KRN23 For The Treatment Of X-Linked Hypophosphatemia
2014-10-27,Ultragenyx Granted Orphan Drug Designation For Triheptanoin For The Treatment Of Glucose Transporter Type-1 Deficiency Syndrome
2014-10-20,Use Options For a Chance To Buy RARE at a 31% Discount
2014-10-13,Ultragenyx Announces Interim Data From Phase 2 Extension Study Of Sialic Acid Extended-Release At International Congress Of The World Muscle Society
2014-09-24,Ultragenyx To Present At The Leerink Partners Rare Disease Roundtable
2014-09-15,Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia
2014-09-04,Ultragenyx To Present At The Morgan Stanley Global Healthcare Conference
2014-09-03,Ultragenyx Announces Positive Interim Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7
2014-08-27,Ultragenyx To Present At The Baird Health Care Conference
2014-08-26,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-12,Ultragenyx Pharmaceutical Stock Sees Short Interest Expand By 33.2%
2014-08-11,Ultragenyx Reports Second Quarter 2014 Financial Results And Corporate Update
2014-08-07,3 Big-Volume Biotech Stocks to Trade for Breakouts
2014-08-06,Ultragenyx To Present At Upcoming Investor Conferences
2014-08-05,Ultragenyx Announces License Of Intellectual Property For The Treatment Of Epilepsy And Other Seizure-Related Disorders With Triheptanoin
2014-07-31,3 Biotech Stocks Breaking Out on Big Volume
2014-07-25,Short Interest In Ultragenyx Pharmaceutical Decreases By 17%
2014-07-23,Ultragenyx Appoints Sunil Agarwal, M.D. As Chief Medical Officer And Senior Vice President
2014-07-21,3 Biotech Stocks Breaking Out on Big Volume
2014-07-14,Ultragenyx Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Option To Purchase Additional Shares
2014-07-09,Ultragenyx Announces Pricing Of Public Offering Of Common Stock
2014-07-07,Ultragenyx Announces Proposed Public Offering Of Common Stock
2014-06-27,'Fast Money' Recap: Rangebound Treasury Yields
2014-06-21,'Mad Money' Lightning Round: Globalstar Is a Real Winner
2014-06-20,Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
2014-04-09,'Fast Money' Recap: S&P Snapback
2014-02-06,Top Insider Trades: DRNA RGLS RARE CARA
2007-09-18,Darden Earnings Jump
2007-08-21,Stockpickr Lists: Buffett Eyeing Countrywide?
2007-08-17,Friday's Winners & Losers: Rare Hospitality
2007-08-16,Darden Buying Rare
2007-07-13,Stock Upgrades, Downgrades from TheStreet.com Ratings
2007-04-27,Restaurants Reeking
2007-03-14,Rare Hospitality's Prospects Juicy
2007-02-16,Friday's Analysts' Upgrades and Downgrades
2007-01-18,Thursday's Analysts' Upgrades and Downgrades
2005-10-20,Stocks in Motion: MoneyGram
2004-02-05,A Rare Find Among Restaurants
2004-01-22,A New Year, a New Barrel
2004-01-16,Restaurant Stocks Survive Mad Cow
2004-01-12,Nasdaq Hits a New 30-Month High
2003-10-08,Restaurant Earnings a Smorgasbord
2003-09-03,Bottom of the Barrel: Old-Timers Take the Field
2003-08-21,Bottom of the Barrel: The Art of the Sale
2003-04-07,Wendy's Same-Store Sales Dip
2003-04-04,Rare Hospitality Sees Earnings Rising
2003-03-19,Bottom of the Barrel: Small-Caps for Uncertain Times
2003-01-09,Bottom of the Barrel: Cleaning Out the Portfolio
2002-07-31,Bottom of the Barrel: Tropical Treat With Hawaiian Electric
2002-07-24,Bottom of the Barrel: What to Do When Everything Sinks
2002-04-10,Bottom of the Barrel: Heads and Tails of the First Quarter
2002-03-13,Bottom of the Barrel: The Portfolio Gets a Spring Cleaning
2002-02-20,Bottom of the Barrel: A Rare Chance in the Restaurant Business
